• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pharvaris N.V.

    6/11/26 6:52:06 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email
    6-K 1 6-k_agm_pr_announcement_.htm 6-K 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2026

    Commission File Number: 001-40010

    Pharvaris N.V.

    (Translation of registrant’s name into English)

    Emmy Noetherweg 2

     

    2333 BK Leiden

     

    The Netherlands
    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.


    PHARVARIS N.V.

     

     

    On June 11, 2026, Pharvaris N.V. (the “Company”) issued a press release announcing its 2026 annual general meeting of shareholders to be held on June 26, 2026 and made available to its shareholders certain other materials in connection with such meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The materials made available to the Company’s shareholders are attached as Exhibits 99.2 and 99.3 hereto and are incorporated by reference herein. Exhibit 99.4 contains the Company’s Annual Report for the year ended December 31, 2025, which is furnished herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    PHARVARIS N.V.

     

     

    Date: June 11, 2026

    By:

    /s/ Berndt Modig

     

    Name:

    Berndt Modig

     

    Title:

    Chief Executive Officer

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

     

     

     

    99.1

     

    Press Release dated June 11, 2026.

    99.2

     

    Convening Notice, including Agenda and Explanatory Notes.

    99.3

     

    Voting Proxy

    99.4

     

    Pharvaris N.V. Annual Report for the year ended December 31, 2025 (prepared in accordance with IFRS-EU).

     


    Get the next $PHVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    4/9/2026$42.00Outperform
    Wolfe Research
    3/9/2026$52.00Outperform
    RBC Capital Mkts
    10/15/2025$60.00Buy
    H.C. Wainwright
    10/9/2025$27.00Underperform → Neutral
    BofA Securities
    6/11/2025$32.00Buy
    Guggenheim
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $PHVS
    SEC Filings

    View All

    SEC Form 144 filed by Pharvaris N.V.

    144 - Pharvaris N.V. (0001830487) (Subject)

    6/15/26 4:55:17 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Pharvaris N.V.

    6-K - Pharvaris N.V. (0001830487) (Filer)

    6/11/26 6:52:06 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Pharvaris N.V.

    144 - Pharvaris N.V. (0001830487) (Subject)

    5/21/26 5:27:32 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

    Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentationEvidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the European Academy of Allergy an

    6/15/26 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Annual General Meeting of Shareholders

    ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the "Investors" section of Pha

    6/11/26 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

    ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Details of the presentations are as follows: Title: Oral Deucrictibant Im

    5/29/26 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Pharvaris N.V. with a new price target

    Wolfe Research initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $42.00

    4/9/26 8:43:44 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pharvaris N.V. with a new price target

    RBC Capital Mkts initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $52.00

    3/9/26 9:07:59 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Pharvaris N.V. with a new price target

    H.C. Wainwright initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $60.00

    10/15/25 8:31:21 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Lu Peng exercised 300 shares at a strike of $2.59 and sold $10,200 worth of shares (300 units at $34.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Pharvaris N.V. (0001830487) (Issuer)

    6/23/26 5:07:28 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Modig Berndt sold $71,173 worth of shares (2,291 units at $31.07) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 135,209 units (SEC Form 4)

    4 - Pharvaris N.V. (0001830487) (Issuer)

    6/17/26 5:51:42 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Lu Peng covered exercise/tax liability with 117 shares, decreasing direct ownership by 0.18% to 65,631 units (SEC Form 4) (withholding obligation)

    4 - Pharvaris N.V. (0001830487) (Issuer)

    6/16/26 5:50:12 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 8:42:52 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 10:27:18 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/13/24 2:14:59 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Announces Appointment of Elisabeth Björk as Board Member

    NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

    6/17/25 7:00:00 AM ET
    $PHVS
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    5/14/24 2:20:00 AM ET
    $KRON
    $MACK
    $MXCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments

    Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

    ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

    11/15/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Financials

    Live finance-specific insights

    View All

    Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

    Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours)Well-tolerated safety profile of deucrictibant confirmedEfficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locationsPharvaris to host a conference call and webcast today at 8:00 a.m. EST ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutica

    12/3/25 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

    CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

    9/5/24 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

    Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

    12/6/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care